frp2 Antibody

What is FRP2 and what are its key characteristics?

FRP2 (Frizzled-Related Protein 2) is a synonym of SFRP2 (secreted frizzled related protein 2), a protein that functions primarily in the Wnt signaling pathway and apoptotic pathway. The human version of FRP2 has a canonical amino acid length of 295 residues and a protein mass of 33.5 kilodaltons . As a secreted protein, FRP2 typically acts as a modulator of Wnt signaling by binding to Wnt ligands and preventing them from interacting with cell-surface receptors.

It's important to note that researchers should be careful not to confuse FRP2/SFRP2 with FPR2 (formyl peptide receptor 2), which is an entirely different protein functioning as a G-protein coupled receptor involved in immune responses . FPR2 is sometimes labeled as FPR2/ALX in the literature and belongs to the formyl peptide receptor family .

What are the primary applications for FRP2 antibodies in research?

FRP2 antibodies enable researchers to detect and measure this protein in various biological samples. Based on available data, the most common applications include:

Western Blot (WB)

Western blotting is widely used for detecting FRP2 in cell or tissue lysates. Commercial antibodies typically work at dilutions of 1:200, as demonstrated in studies using human HL-60 promyelocytic leukemia and K562 chronic myelogenous leukemia cell lysates . The expected band size would correspond to approximately 33.5 kDa, though post-translational modifications may alter the apparent molecular weight.

ELISA (Enzyme-Linked Immunosorbent Assay)

ELISA is commonly employed for quantitative measurement of FRP2 in solution. Both direct and sandwich ELISA formats can be used depending on the specific experimental requirements .

Immunohistochemistry (IHC)

Some FRP2 antibodies are validated for immunohistochemistry applications, allowing for the localization of the protein in tissue sections. Research indicates successful application in tissues such as human minor salivary glands .

Flow Cytometry

Flow cytometric analysis can be performed using cell-surface detection approaches, particularly when working with live intact cells. This has been demonstrated using human THP-1 monocytic leukemia cells with anti-FRP2 antibodies .

How do you validate the specificity of an FRP2 antibody?

Antibody validation is critical for ensuring experimental reproducibility and data reliability. For FRP2 antibodies, implement these methodological approaches:

Blocking Peptide Competition

Pre-incubate the antibody with a synthetic peptide corresponding to the immunogen epitope, then compare signal between blocked and unblocked antibody conditions. Search results demonstrate this approach with Human FRP2 (extracellular) Blocking Peptide, showing elimination of specific binding in Western blot analysis of human cell lysates .

Positive and Negative Controls

Use cell lines with confirmed FRP2 expression as positive controls. Based on available data, HL-60 promyelocytic leukemia cells and K562 chronic myelogenous leukemia cells express detectable levels of FRP2 and can serve as positive controls in Western blot applications .

Multiple Detection Methods

Confirm findings using orthogonal techniques. For instance, if using Western blot as your primary detection method, validate observations with immunofluorescence or ELISA to ensure consistency across different detection platforms.

Cross-Reactivity Assessment

Evaluate antibody performance across species and related proteins. Commercial FRP2 antibodies show variable reactivity profiles, with some demonstrating specificity for human samples while others cross-react with mouse and rat tissues .

What are optimal conditions for using FRP2 antibodies in Western blot?

Successful Western blot detection of FRP2 requires optimization of several parameters:

Sample Preparation

• Harvest cells or tissues in appropriate lysis buffers containing protease inhibitors to prevent degradation

• For detecting secreted FRP2, collect and concentrate culture media or use serum/plasma samples

• Consider using specialized precipitation methods for secreted proteins if standard approaches yield weak signals

Protocol Optimization

• Protein loading: 20-50 μg total protein per lane for cell/tissue lysates

• Gel percentage: 10-12% acrylamide for optimal separation around 33.5 kDa

• Transfer conditions: Standard PVDF or nitrocellulose membranes

• Blocking solution: 5% non-fat milk or 3% BSA in TBST (determine empirically which works better)

• Primary antibody dilution: Start with 1:200 as demonstrated in successful studies

• Primary antibody incubation: Overnight at 4°C for optimal sensitivity

• Detection system: Standard HRP-conjugated secondary antibodies with chemiluminescence detection

Troubleshooting Tips

If experiencing weak or absent signal:

• Increase protein loading or antibody concentration

• Extend primary antibody incubation time

• Consider using signal enhancement systems

• Verify protein transfer efficiency with reversible staining

If detecting multiple bands:

• Use blocking peptide competition to identify specific bands

• Modify sample preparation to reduce degradation

• Consider the possibility of post-translational modifications or isoforms

How can FRP2 antibodies be applied to study Wnt signaling dysregulation?

FRP2/SFRP2 is a key modulator of Wnt signaling, making its antibodies valuable tools for investigating pathway dysregulation:

Co-Immunoprecipitation Studies

• Use FRP2 antibodies to pull down protein complexes

• Identify interactions with Wnt ligands or receptors

• Analyze how disease conditions alter these protein-protein interactions

Immunofluorescence Analysis

• Visualize spatial relationships between FRP2 and Wnt pathway components

• Perform dual or triple labeling with antibodies against FRP2, Wnt ligands, and Frizzled receptors

• Use confocal microscopy for high-resolution co-localization analysis

Expression Analysis in Disease Models

Compare FRP2 expression between normal and pathological samples using validated antibodies. Potential research applications include:

How do post-translational modifications affect FRP2 antibody detection?

Post-translational modifications can significantly impact antibody recognition of FRP2, affecting experimental outcomes:

Glycosylation Effects

FRP2 may undergo glycosylation, potentially masking epitopes or altering apparent molecular weight in gel-based applications. When inconsistent results are observed:

• Compare samples with and without enzymatic deglycosylation (PNGase F, Endo H)

• Run treated and untreated samples in adjacent lanes

• Observe for molecular weight shifts indicating glycosylation

Phosphorylation Considerations

Potential phosphorylation sites may create or block antibody binding epitopes:

• Use phosphatase treatment as control

• Consider phospho-specific antibodies if phosphorylation status is critical to research question

• Compare reducing and non-reducing conditions, particularly important for FRP2's cysteine-rich domains

What methodologies support the use of FRP2 antibodies in immunofluorescence studies?

For optimal immunofluorescence detection of FRP2:

Tissue Section Protocol

• Section preparation: Use properly fixed tissue sections (4-6 μm thickness)

• Deparaffinization and rehydration (for FFPE samples)

• Antigen retrieval: Heat-mediated in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Blocking: 5-10% normal serum in PBS with 0.1-0.3% Triton X-100

• Primary antibody incubation: Anti-FRP2 at optimized dilution (typically 1:100-1:200)

• Secondary antibody: Fluorophore-conjugated appropriate for imaging system

• Counterstaining: DAPI for nuclear visualization

• Mounting with anti-fade media

Cell Culture Applications

For cultured cells, consider:

• Fixation method: 4% paraformaldehyde typically preserves antigen recognition

• Permeabilization: 0.1% Triton X-100 for intracellular epitopes

• Co-staining with markers for cellular compartments to determine subcellular localization

How can researchers troubleshoot inconsistent results with FRP2 antibodies?

When facing technical challenges with FRP2 antibody applications, implement this systematic approach:

General Troubleshooting Framework

• Confirm antibody quality and specificity using validation methods

• Systematically test critical variables one at a time

• Include positive and negative controls in every experiment

• Document detailed protocols, including lot numbers and experimental conditions

Western Blot-Specific Troubleshooting

ELISA Troubleshooting

What considerations apply when using FRP2 antibodies across different experimental models?

When applying FRP2 antibodies in diverse experimental systems:

Species Cross-Reactivity

Verify the species reactivity of your selected antibody. Commercial FRP2 antibodies show varying reactivity profiles:

• Human-specific antibodies

• Antibodies reacting with human, mouse, and rat (Hu, Ms, Rt)

• Antibodies with reactivity to bacterial or yeast proteins (likely different epitopes)

Experimental Model Considerations

What emerging applications exist for FRP2 antibodies in neurological research?

While traditional FRP2 research has focused on development and cancer, emerging evidence suggests roles in neurological contexts:

Potential Neurological Applications

• Investigating FRP2 expression in neurodevelopmental disorders

• Studying the relationship between Wnt signaling and neurodegenerative conditions

• Examining FRP2's potential role in neuroinflammatory processes

When designing neurological studies using FRP2 antibodies, researchers should:

• Optimize protocols specifically for neural tissues

• Consider region-specific expression patterns

• Combine with neuronal and glial markers for precise cellular localization

• Be careful to distinguish FRP2/SFRP2 from FPR2, as the latter has been specifically studied in neurological contexts such as social isolation-induced depression

Immunofluorescence protocols for brain tissue may require specific methodological adaptations:

• Modified fixation to preserve brain architecture

• Antigen retrieval optimization for neural tissue

• Careful blocking of endogenous peroxidases and biotin

• Extended incubation times for thick sections